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Is Otilonium Bromide Really Effective for Treating 
Asian Patients With Irritable Bowel Syndrome?
TO THE EDITOR: Irritable bowel syndrome (IBS) is a complex 
and very common disease. It is a condition characterized by ab-
dominal pain/discomfort associated with disordered defecation in 
the absence of any organic abnormalities. Although the exact 
pathophysiology of IBS is not fully understood, the treatment of 
IBS is targeted at the management of abdominal pain/discomfort 
including pharmacotherapy with antispasmodics.
1 Mebeverine is 
a musculotropic agent that has antispasmodic activity and regu-
latory effects on the bowel functions, and has been effectively 
used in the treatment of IBS for many years.
2 Otilonium bromide 
(OB) is a quaternary ammonium compound whose spasmolytic 
action is mainly due to its direct myolytic properties.
3 In the 
meta-anlaysis of smooth muscle relaxants in the treatment of IBS, 
both mebeverine and OB were superior to placebo in relieving 
symptoms such as abdominal pain and distension without adverse 
effects.
4 In addition, a double-blind, placebo-controlled study 
among Italian IBS patients showed that the reduced episode of 
abdominal pain was higher in OB treated patients (53.3%) than 
in placebo patients (39.9%).
5
With great interest, I read the report by Chang et al
6 regard-
ing “The evaluation of otilonium bromide treatment in Asian pa-
tients with IBS.” In this study, overall 117 IBS patients meeting 
Rome II criteria were enrolled in an 8-week trial, and random-
ized participants received either OB 40 mg or mebeverine 100 
mg 3 doses daily. The primary endpoints were to evaluate the 
changes of abdominal pain/discomfort frequency scores (APDFS) 
and safety profile. The authors showed that the reduced APDFS 
in OB and mebeverine were 0.55 ± 1.20 (P = 0.011) and 0.37 
± 1.11 (P = 0.042), respectively, after 8-week treatment com-
pared to baseline. The most reported side effects were dry mouth, 
nausea and dizziness. OB was not inferior to mebeverine in treat-
ing IBS patients with alleviations in abdominal pain intensity, 
flatulence and abdominal bloating. These results suggest that OB 
is as effective as mebeverine for alleviating IBS symptoms in 
Oriental populations.
Although the authors showed an important result of OB 
treatment for Asian IBS patients, there are a few limitations re-
garding this study. First, the dose of mebeverine used was 400 
mg per day in the previous study, but mebeverine of 300 mg was 
used in this study.
2 I wonder whether the lower dose of mebever-
ine may have influence on the results or not, but there was no ex-
planation about this in the discussion. Second, I also wonder if 
there was any difference in the reduction of APDFS according to 
the subgroup of IBS patients. It has been known that mebeverine 
is more effective than placebo in the management of diar-
rhea-predominant IBS patients by diminishing stool frequency, 
but there is few data about the effect of OB on stool frequency.
7 
Third, the number of patients receiving rescue treatment were 
very high (100% in OB and 98% in mebeverine). As mentioned 
in the discussion, patients were very concerned about the abnor-
mal bowel movement activity during the treatment, therefore the 
rescue treatment might have been helpful for relieving their psy-
chological stress. However, is there any possibility that this high 
portion of rescue therapy may affect the result by decreasing the 
differences of APDFS between the 2 groups?
Despite these limitations of the present study, it provides us 
with the important information in the management of IBS pa-
tients in Asian, because it is the first trial of OB in Asia. Further 
large-scaled studies are needed to validate the results of the pres-
ent study.
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